Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Data demonstrates Ronapreve reduced risk of hospitalisation in certain patients and reduced risk of symptomatic Covid-19 infections in people exposed to the virus
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The company is a medical dictation solution used by medical practitioners
Support from DFC will help produce one billion vaccine doses by the end of 2022
This strategic collaboration will enable continued innovation in cancer care
Subscribe To Our Newsletter & Stay Updated
